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Abstract
The MUC1 protein is aberrantly expressed on many solid tumor cancers. In contrast to its apical clustering on healthy
epithelial cells, it is uniformly distributed over cancer cells. However, a mechanistic link between aberrant expression and
cancer has remained elusive. Herein, we report that a membrane-bound MUC1 cleavage product, that we call MUC1*, is the
predominant form of the protein on cultured cancer cells and on cancerous tissues. Further, we demonstrate that
transfection of a minimal fragment of MUC1, MUC1*1110, containing a mere forty-five (45) amino acids of the extracellular
domain, is sufficient to confer the oncogenic activities that were previously attributed to the full-length protein. By
comparison of molecular weight and function, it appears that MUC1* and MUC1*1110 are approximately equivalent.
Evidence is presented that strongly supports a mechanism whereby dimerization of the extracellular domain of MUC1*
activates the MAP kinase signaling cascade and stimulates cell growth. These findings suggest methods to manipulate this
growth mechanism for therapeutic interventions in cancer treatments.
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Introduction
MUC1 is a Type I membrane glycoprotein of the mucin family
having an extensive extracellular domain consisting of hundreds of
tandem repeat units, a single transmembrane domain and a C-
terminal cytoplasmic tail [1–5]. MUC1 is normally expressed at
the apical border of healthy epithelia that line the respiratory,
reproductive and gastrointestinal tracts. In sharp contrast to the
healthy pattern of expression that restricts MUC1 to luminal
surfaces, cancerous tissues display an aberrant expression pattern
wherein MUC1 is uniformly distributed over the entire tissue
surface [6,7]. It is currently estimated that 75% of all human solid
tumor cancers aberrantly express the MUC1 protein [8].
The function of MUC1 in the healthy state remains unclear,
while evidence is rapidly accumulating for its role as an
oncoprotein. The introduction of MUC1 into previously MUC1-
negative cells results in an increased growth rate [9], enables
anchorage-independent cell growth [10] and renders cells resistant
to apoptosis induced by treatment with standard chemotherapy
agents [8]. Interactions between MUC1 and members of the ErbB
family have been reported [11,12]. MUC1 is involved in several
intracellular signaling pathways. These studies have focused on the
MUC1 cytoplasmic tail (MUC1-CT), which is perhaps the best
characterized portion of the protein [13]. The 72 amino acid tail
bears residues that can be phosphorylated by Zap70, PCKd,
GSK3b, ErbB1, c-Src, Lyn, and Lck. In addition, signal
transduction elements AP-2, p53, ER-a, b-catenin and Grb2 have
been shown to bind to the MUC1-CT, presumably as a function of
its phosphorylation state. Indeed, studies implicate the phosphor-
ylation of the MUC1-CT in the activation of the MAP kinase
signaling pathway [12]. In one such study [14], antibody
stimulation of the extracellular domain of a chimeric protein
comprised of the extracellular and transmembrane portions of
CD8, but the cytoplasmic tail of MUC1, resulted in the
phosphorylation of ERK 1/2. ERK activation was shown to be
dependent on the phosphorylation of the MUC1-CT and could be
abolished by a dominant negative Ras mutant or by a MEK
inhibitor, thus arguing that the MUC1-CT mediates the Grb2-
SOS-Ras-MEK-ERK signaling cascade which leads to cell
division.
Studies of the MUC1 extracellular domain (ECD) are
complicated by its shear size (150–300 kDa), the fact that it is
highly glycosylated, and that it is made up of a variable number of
tandem repeats. In addition, the protein can be cleaved, then shed
from the cell surface. Shed MUC1, comprised largely of tandem
repeats, can be detected in the serum of Stage II breast cancer
patients [15]. Similarly, western blots of the lysates of MUC1-
positive cultured cancer cells show two MUC1 species: a high
molecular weight species (150–300 kDa) that reacts with antibod-
ies that bind to the tandem repeats and a low molecular weight
species (20–35 kDa) that reacts with antibodies that bind to the
cytoplasmic tail. Cell supernatants contain only the high molecular
weight MUC1 species. Some studies provide evidence that MUC1
self-cleaves via an SEA domain within the protein [16,17]. Others
have presented evidence that TACE (ADAM 17) and MMP14
(MT1-MMP) cleave MUC1 [18,19]. Early reports postulated that
after MUC1 cleavage, the released, high molecular weight portion
re-associates with the membrane bound low molecular weight
fragment, thus becoming the ligand for the membrane-bound
receptor [20].
The present report focuses on the expression and function of the
low molecular weight MUC1 cleavage product that remains
PLoS ONE | www.plosone.org 1 April 2008 | Volume 3 | Issue 4 | e2054membrane-bound after the bulk of the extracelluar domain has
been cleaved and released from the cell surface.
Results
Characterization of a novel MUC1 antibody
In order to investigate the expression patterns of MUC1 and its
cleavage product as well as their respective functions, we needed to
develop antibodies that could distinguish the low molecular weight
cleavage product from the full-length protein on intact cells and
tissue specimens. Antibodies that recognize the tandem repeat
motifs (VU4H5, Santa Cruz) and the cytoplasmic tail (Ab-5,
LabVision) are commercially available (Fig. 1A). However,
antibodies that recognize the extracellular portion of the
membrane-bound cleavage product are not. To complicate
matters, the exact site(s) at which MUC1 is cleaved on cancer
cells is unclear. Several cleavage sites for MUC1 have been
reported or postulated [21,22]. In fact, one of the enzymes that
cleaves MUC1, MMP14, can cleave its substrates at multiple sites
[23]. However, no cleavage site that has been reported or
proposed would produce a membrane bound fragment with an
extracellular domain shorter than forty-five (45) amino acids.
Therefore, we raised an antibody against the forty-five (45) amino
acid peptide (N-1110-1154-C) that is immediately N-terminal to
the transmembrane domain (Fig. 1B). We reasoned that this
antibody would recognize the membrane-bound products of all
reported or proposed cleavage sites. Due to the uncertainty of the
precise position of MUC1 cleavage, herein, we generically refer to
all membrane-anchored MUC1 cleavage products as MUC1*.
Similarly, we refer to antibodies raised against the forty-five amino
acid peptide (N-1110-1154-C) as Anti-MUC1*. Both polyclonal
and monoclonal antibodies were generated and they essentially
performed equivalently.
Anti-MUC1* antibodies were characterized by western blot,
FACS, and immunocytochemistry. Figure 1C shows a western blot
in which cell lysates from a panel of MUC1-positive cultured
cancer cells were probed with either VU4H5 (upper gel) or Anti-
MUC1* (lower gel). As expected, VU4H5 stained the high
Figure 1. Schematic and antibody recognition of full-length MUC1 versus the membrane-bound cleavage product MUC1*. A. Full-
length MUC1 protein is comprised of a cytoplasmic tail (CT), a transmembrane domain (TM), a self-aggregation domain (SAD), and hundreds of
tandem repeats (TRs). B. Cleavage product, MUC1*, consists of the cytoplasmic tail, transmembrane domain, and at least 45 amino acids of the
extracellular domain (ECD). Although the exact site(s) of cleavage remain somewhat uncertain, to our knowledge, no cleavage sites have been
reported that leave less than a 45 amino acid ECD. Binding sites for antibodies VUH5, Ab-5 and Anti-MUC1* are marked. C. Western analysis of whole
cell lysates of MUC1-positive cultured cancer cells, Lanes 1–6, are compared to MUC1-negative cells, Lanes 7–9. A 6% gel (upper) was blotted with
VU4H5 and a 12% gel (lower) was blotted with Anti-MUC1*. D. T47D, MUC1-positive cultured breast cancer cells, were immunoprecipitated with
either Ab-5 or Anti-MUC1*. Samples of the whole cell lysate (WCL), Lane 1, or the immunoprecipitates, Lanes 2 and 3, were analyzed by western blot.
Gels were probed with either VU4H5 (upper) or Anti-MUC1* (lower). E. Western analysis of three MUC1-positive breast cancer cell lines pre- and post-
deglycosylation and blotted with Anti-MUC1* shows that the actual molecular weight of cleaved MUC1 is approximately 16–18 kDa. F. The table
summarizes the reactivities of antibodies to either full-length MUC1 (Hi MW) or cleaved MUC1 (Lo MW).
doi:10.1371/journal.pone.0002054.g001
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tested: T47D, ZR-75-1, ZR-75-30, BT474, DU145, and Capan 2.
Anti-MUC1* stained a low molecular weight 20–35 kDa protein
band that appeared to be specific for MUC1. MUC1-negative
cells, HCT116, 3Y1, and HEK293, did not react with either
antibody. To confirm that the low molecular weight species that
reacted with Anti-MUC1* was indeed MUC1, lysates from
MUC1-positive tumor cells were immunoprecipitated with either
Ab-5 (cytoplasmic tail antibody) or Anti-MUC1*, then analyzed
by western blot (Fig. 1D). Anti-MUC1* binds to the same low
molecular weight species that Ab-5 recognizes, thus confirming
that Anti-MUC1* binds to the low molecular weight MUC1
cleavage product.
As previously reported, by western blot analysis, the high
molecular weight MUC1 species only reacted with antibodies
directed against the tandem repeats, and did not react with Anti-
MUC1* or Ab-5 (data not shown). However, both antibodies are
able to weakly immunoprecipitate the high molecular weight
species (Fig. 1D, upper gel). In these experiments, immunopre-
cipitation may simply bring down a non-covalently associated
hetero-dimer of the two cleavage fragments. These results might
also be explained by the fact that VU4H5 binds to a tandem
repeat unit that is repeated hundreds of times per receptor while
Anti-MUC1* and Ab-5 bind to non-repeating sequences that
occur only once per receptor. Alternatively, these results might
simply be explained by the fact that the major species on cancer
cells is the cleaved form, MUC1*. The table of Figure 1
summarizes the antibody binding data.
To further explore the actual size of the low molecular weight
MUC1 species, cell lysates were deglycosylated prior to western
blot analysis. Figure 1E shows that after deglycosylation, the
previously broad 20–35 kDa protein band converges to a discrete
band that runs with an apparent molecular weight of about 15–
17 kDa. We note that the calculated molecular weight of a MUC1
cleavage product, trunacted after about forty-five amino acids of
the extracellular domain is approximately 16 kDa.
Expression Patterns of MUC1 and its Cleavage Product,
MUC1*, on Cultured Cells and on Cancerous Tissues
Cultured cancer cells were analyzed by immuno-cytochemistry
to determine the expression pattern of MUC1 and its cleavage
product MUC1*. MUC1-positive breast cancer cells were double
stained with VU4H5 that binds to tandem repeats units in the high
molecular weight fragment and Anti-MUC1* that binds to the low
molecular weight, membrane-bound cleavage product, MUC1*.
Fluorescent imaging revealed that MUC1* is the predominant
form of protein on cultured cancer cells and is uniformly
distributed over the entire cell surface. In contrast, proteins that
were stained by VU4H5 were either not present at all or were the
minor species (Fig 2A). VU4H5 staining could indicate that the
protein on the surface is full-length MUC1 or that it is a non-
covalently bound hetero-dimer consisting of both cleavage
products. Notably, the pattern of expression of full-length
MUC1 is clustered at one or two points on the cell surface, which
is reminiscent of the tendency of MUC1 on healthy epithelium to
cluster at the apical border.
We next looked at the expression pattern of full-length MUC1
versus MUC1* healthy and cancerous human tissue specimens
from untreated patients. Serial sections of a non-cancerous
fallopian tube were stained with either Anti-MUC1* or VU4H5.
Both MUC1 antibodies stained the luminal surface of the fallopian
tube but not the surrounding tissue (Fig. 2B, upper panels). 100-
fold magnification revealed that the cleaved form, MUC1*, is
exclusively expressed on the surface of the epithelial cells lining the
tube, while the full-length MUC1 protein appears to be limited to
the cytoplasm (Fig. 2B, lower panels). Back-to-back sections of
cancerous breast, lung, and colon tissues were similarly probed
with the two antibodies (Figs. 2C–E, respectively). In sharp
contrast to the expression pattern of MUC1 on healthy tissues,
which was confined to the luminal edge, MUC1 is expressed over
the entire surface of cancerous tissues. Staining with Anti-MUC1*
shows that, like on cultured cancer cells, the major form of MUC1
on cancerous tissues is MUC1*. Magnified images show that
MUC1* is expressed on the cell surface while full-length MUC1
appears to be cytoplasmic (Figs. C, D, lower panels). Notably,
Anti-MUC1* produced heavier staining than VU4H5 despite the
fact that the tandem repeat antibody can bind to hundreds of
epitopes per receptor compared to the single epitope to which
Anti-MUC1* binds. Some of the cancerous tissues that we tested
did not stain positive with either MUC1 antibody. Of nine (9)
breast cancer specimens tested, only one was a MUC1-negative
cancer, which roughly corresponds to published reports that
approximately 90% of all breast cancers are MUC1-positive
cancers. We note that tissue specimens that were deemed to be
MUC1-negative cancers showed normal apical staining with both
MUC1 antibodies in regions outside of the margin of malignancy
(data not shown) confirming that the assay was correctly
performed but that these cancers were not characterized by
aberrant expression of MUC1.
Importantly, we noticed that some tissue specimens stained
positive for the presence of MUC1* but negative for full-length
MUC1. For example, a colon cancer specimen was stained by
Anti-MUC1* with the most intense staining occurring in the most
diseased portions of the specimen. In contrast, VU4H5 lightly
stained areas close to the margin of malignancy but produced no
staining in the more diseased regions, characterized by the loss of
cellular architecture (Fig. 2E). These results are consistent with the
idea that the most cancerous specimens may appear to be MUC1-
negative if probed with antibodies against the full-length protein
alone. Taken together, these results demonstrate that the
predominant MUC1 species on cancerous tissue, as on cultured
cancer cells, is the cleaved species, MUC1*.
MUC1* mediates cell growth
After determining that the major species on the surface of
cancer cells and tissues is MUC1* and not the full-length protein,
we decided to study the growth characteristics of the cleaved form
compared to uncleaved. MUC1-negative cells, 3Y1 and HCT116,
were transfected with either full-length MUC1 or a construct,
MUC1*1110, whose extracellular domain was terminated after
forty-five (45) amino acids (N-1110-1255-C) (Fig. 1B). Stable
transfectants turned out to be inadequate for study because the
full-length transfectants quickly evolved into a population
dominated by the cleaved form, MUC1*, having little or no full-
length protein available on the cell surface (data not shown). For
this reason, single cell clones were generated and used in the
experiments described in the present study. FACS, immunocyto-
chemistry and Western blot analysis showed that our single cell
clones of full-length MUC1 produced the full-length protein but
also generated the cleavage product MUC1* (Fig. S1).
A clonogenic assay was performed to assess the growth rate of
MUC1*1110 versus full-length MUC1 that had been transfected
into rat fibroblast 3Y1 cells. Cells plated at low density were
allowed to grow for nine (9) days. Resultant colonies were
visualized by staining with crystal violet. MUC1*1110 clones, 3Y1
MUC1* 3 and 3Y1 MUC1* 44, produced more, bigger and
denser colonies than full-length clones, 3Y1 MUC1 8 and 3Y1
MUC1 17 (Fig. 3A). At the end of nine days, the MUC1*1110
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clones. The difference in growth was quantified by measuring the
amount of crystal violet that was released from the cells on each
plate (Fig. 3A: bar graph). However, the increase in the number of
cells could have been due to an increase in the survival rate or an
increase in the growth rate. Cell survival factors can be identified
by their ability to render cells resistant to chemotherapy-induced
death. Single cell clones of MUC1 or MUC1*1110 that had been
transfected into MUC1-negative cells (3Y1 or HCT116) were
treated with AraC, cisplatin or etoposide, then assayed to measure
the amount of cell death. Cells transfected with either full-length
MUC1 or MUC1*1110 became resistant to apoptosis induced by
these chemotherapy agents. A representative experiment is shown
in Figure 3B. These results argue that MUC1 or MUC1* increase
cell survival. To determine whether they also increase cell growth,
a cell cycle analysis experiment was performed. FACS was used to
measure the number of cells in G2/M phase (an indicator of cell
division) compared to the number in G1 phase. The ratio of cells
in G2:G1 was measured for HCT116 cells transfected with either
full-length MUC1 or MUC1*1110 (Fig. 3C). The introduction of
either MUC1*1110 or full-length MUC1 drove more cells into the
G2/M phase than the control transfection of the empty vector.
However, transfection MUC1*1110 increased the ratio of G2:G1
more than the transfection of the full-length proetin. Recall that
although cells are transfected with the full-length protein, a
considerable amount is proteolyzed to the MUC1* form.
Thus, having established a link between MUC1* and growth,
we speculated that it may function as a growth factor receptor.
Without a known ligand for MUC1 or MUC1*, it would be
difficult to test the hypothesis. However, Class I growth factor
receptors trigger cell growth via the dimerization of the
extracellular domain of the receptor. We did have a bivalent
antibody against the MUC1*1110-ecd (extracellular domain) portion,
which could be used to simulate its ligand. Others had previously
reported that stimulation of this class of growth factor receptors
with dimerizing antibodies generated bell-shaped growth curves
[24–26]. This is because cell growth increases with increasing
antibody concentration until maximal growth is achieved when
one antibody dimerizes every two receptors. However, as the
concentration of antibody goes to excess, each antibody binds to
one receptor, so no dimerization occurs, and cell growth falls off.
We performed similar experiments by treating MUC1-positive
cancer cells as well as MUC1 and MUC1*1110 transfected cells
with Anti-MUC1*. As a negative control, we treated cells with the
monovalent Fab of Anti-MUC1*, which would not be able to
dimerize the receptors. For each MUC1-positive or MUC1*1110-
positive cell line that we tested, the bivalent antibody stimulated
cell growth and produced the expected bell-shaped growth curve.
In stark contrast, the monovalent Fab not only did not stimulate
cell growth, but it induced cell death. The results of one such
experiment is shown in Figure 3D, where the growth of MUC1-
positive breast cancer cells, ZR-75-30s, is stimulated by Anti-
MUC1* and inhibited by the monovalent Fab. MUC1-negative
HEK293 cells are unaffected by either antibody. Control
antibodies, whether bivalent or monovalent, had no effect on
the growth of MUC1-positive tumor cell growth (Fig. S2). To
Figure 2. MUC1* is the major species on cultured cancer cells
and on human tumor tissue. A. Fluorescent imaging of cultured
breast cancer cells shows that the cleavage product MUC1* (red) is the
predominant species and is uniformly distributed over the entire cell
surface. Full-length MUC1 (green) is the minor species and is clustered.
Cells were double stained with Anti-MUC1* (red) that binds to an
epitope within the membrane proximal first 45 amino acids of the
extracellular domain and VU4H5 (green) that binds to an epitope within
the tandem repeat domain of the full-length protein. B–E. Pairs of
contiguous sections of human tissue specimens from untreated
patients were stained with either Anti-MUC1* (left) or VU4H5 (right).
Images were photographed at 106or 1006magnification. B. A cross
section of a non-cancerous fallopian tube shows MUC1* surface
staining at the luminal edge (lower left). Full-length MUC1 is
cytoplasmic (lower right). C. Breast cancer tissue specimens. D. Lung
cancer specimens. E. Colon cancer specimens. Arrows point to the most
involved portions of the cancerous tissue where all cellular architecture
has been lost and tissue is not stained by VU4H5.
doi:10.1371/journal.pone.0002054.g002
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PLoS ONE | www.plosone.org 4 April 2008 | Volume 3 | Issue 4 | e2054Figure 3. MUC1* mediates growth factor receptor-like activity. A. A clonogenic assay was performed on single cell clones of MUC1-negative
3Y1 cells that had been transfected with either an empty vector, full-length MUC1 or MUC1*1110. A photograph of Petri dishes containing cells plated
at 1000 cells per 100 mm, grown for 9 days, then stained with crystal violet. Bar graph quantifies growth of each clone. Crystal violet absorbed by the
cells on each plate was released and absorbance at 590 nm was measured on a spectrophotometer. Absorption measurements were normalized to
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specifically mediated by MUC1, the experiments were repeated
using MUC1-positive breast cancer cells, T47Ds, that had been
stably transfected with siRNA to knockdown MUC1 expression.
T47D cell growth is stimulated by the addition of bivalent Anti-
MUC1* and the characteristic bell-shaped growth curve is
produced. However, in cells in which MUC1 expression has been
suppressed by at least 90%, the antibody has no stimulatory effect
(Fig. 3E). Lastly, experiments showed that stimulation of MUC1-
positive cells with bivalent Anti-MUC1* induced the phosphor-
ylation of ERK1/2. In contrast, the monovalent Fab fragment of
Anti-MUC1* suppressed basal levels of phosphorylated ERK1/2
(Fig. 3F). The phosphorylation of ERK1/2 is a key step in the
activation of the MAP kinase signaling cascade. Taken together,
these results are consistent with the idea that MUC1* is a growth
factor receptor or co-receptor that mediates cell growth via
dimerization of the extracellular domain, whereupon the MAP
kinase signaling pathway is activated.
MUC1* activating ligands
If MUC1 or MUC1* functions as a growth factor receptor that
is activated by dimerization of the extracellular domain, then it
follows that MUC1-positive cancer cells may secrete a dimerizing
ligand(s). We designed a nanoparticle experiment to screen cancer
cell lysates and supernatants for the presence of this ligand.
MUC1*1110-ecd peptides (N-1110-1054-C: see Fig. 1B) were
attached to gold nanoparticles via a C-terminal histidine tag and
lysate/supernatant samples were added [27]. If a dimerizing
ligand were present, it would simultaneously bind to a first peptide
on a first nanoparticle and a second peptide on a second
nanoparticle, thus causing bulk crosslinking of nanoparticles and
peptides. Due to an inherent property of gold nanoparticles,
crosslinking causes a color change from the characteristic pink to a
purple/blue [28]. The addition of the lysate/supernatant mixtures
to MUC1*1110-ecd peptide-bearing nanoparticles caused the
solution to turn purple/blue. The rate of color change roughly
corresponded to the amount of MUC1 that each cell line
produced. No color change resulted when the lysate/supernatant
mixtures were added to nanoparticles bearing a control peptide
(Fig. 4A).
To identify what appeared to be a MUC1* ligand(s), beads
bearing MUC1*1110-ecd peptides were used to immunoprecipitate
the unknown proteins from the lysate/supernatant mixtures from
MUC1-positive cancer cells. The eluates were separated by SDS-
PAGE and visualized using silver staining methods. There were
essentially only two bands that were precipitated by the
MUC1*1110-ecd peptide and not precipitated by a control peptide:
a prominent 23 kDa band and a fainter 17 kDa band (Fig. S3).
The protein bands were excised from the gel and analyzed using
N-terminal microsequencing, which identified them as NM23,
isoforms H1 and H2 respectively. NM23 is normally found in the
cytoplasm of all cells but is often secreted by cancer cells [29]
indicating that it could be a ligand for the extracellular portion of
MUC1*. Cell supernatants were immunoprecipitated with
MUC1*1110-ecd peptides attached to beads, then analyzed by
western blot. The supernatants from MUC1-positive cancer cells,
but not the control cells, generated a strong protein band at
approximately 23 kDa that reacted with anti-NM23H1 (Fig. 4B).
This confirmed that the proteins in the cancer cell supernatants
that were immunoprecipitated with MUC1*1110-ecd peptides were
indeed NM23.
To detect direct binding between NM23 and MUC1*1110-ecd
peptides and to confirm specificity, another nanoparticle exper-
iment was performed. Recombinant human NM23 was added to
MUC1*1110-ecd-peptide-bearing nanoparticles or nanoparticles
bearing a control peptide. The addition of NM23 to nanoparticles
bearing MUC1*1110-ecd, caused a solution color change from pink
to purple/blue and the degree of the color change was a function
NM23 concentration. The monovalent Fab of Anti-MUC1*
competitively inhibited binding between particle-immobilized
MUC1* peptides and NM23 (Fig. 4C). To further demonstrate
the specificity of the nanoparticle assay itself, bivalent Anti-MUC1
was added to MUC1*1110-ecd-peptide-bearing nanoparticles,
which as expected resulted in the pink to blue color change. That
binding was also competitively inhibited by the monovalent Fab
(Fig. 4D). Together, these results indicate that NM23 directly
binds to the MUC1*1110-ecd peptides and that the binding is
specific and multimeric.
The binding of NM23 to MUC1* peptides was also demon-
strated using a Biacore surface plasmon resonance (SPR)
instrument and methods described in Bamdad [30]. SPR
techniques measure changes in optical properties at a solution/
surface interface when proteins in a flowing solution bind to a
target protein that has been immobilized on the surface. Because
binding takes place in a constant flow environment, the technique
can be used to extract binding constants and affinities. We
immobilized MUC1*1110-ecd-peptides on the surface and injected
NM23 into the flowing buffer. Our experiments showed that
purified bovine as well as recombinant human NM23 specifically
bound to MUC1*1110-ecd peptide surfaces at concentrations as low
as 1 nM, but not to surfaces that presented an irrelevant peptide of
similar size (Fig. 4E). Subsequent binding of an antibody that
recognizes NM23 verified that the change in optical readout at the
solution-surface interface was due to the binding of NM23 to the
MUC1*1110-ecd peptide surface. Pico- to nanomolar affinities were
measured by analyzing the resultant binding curves with
BiaEvaluation software.
We next tested the ability of exogenous NM23 to stimulate the
growth of MUC1-positive cancer cells. T47D breast cancer cells
were stably transfected with either siRNA that suppressed MUC1
the amount of crystal violet released from the empty vector clone. Nomenclature for our single cell clones is ‘‘parent cell name/construct/clone #’’. B.
Resistance to cell death induced by the chemotherapy drug AraC is tested in single cell clones of either empty vector, full-length MUC1 or MUC1*
transfected into 3Y1 cells. C. Cell cycle analysis was performed on either empty vector, full-length MUC1 or MUC1* transfected into MUC1-negative
cell line HCT116. The ratio of the percentage of cells in G2 to G1 phase is plotted as a function of serum concentration. The ratio of %G2:%G1 for the
empty vector transfectants has been normalized to 1. D. The growth of MUC1-positive breast cancer cells, ZR-75-30, is stimulated by the addition of
bivalent (bv) Anti-MUC1* and inhibited by the addition of the monovalent (mv) Fab. The addition of bivalent antibody produces the bell-shaped
growth curve that is characteristic of receptor dimerization. The growth of MUC1-negative HEK 293 cells was not impacted by either the bivalent or
monovalent Anti-MUC1*. E. The stimulation of growth by the addition of bivalent Anti-MUC1* is tested using stably transfected siRNA to suppress
MUC1 expression in breast cancer cell line T47D. Bivalent Anti-MUC1 stimulated growth in cells transfected with control siRNA, but did not
significantly effect growth in the MUC1 suppressed cells. Western blot analysis (insert) shows that MUC1 siRNA suppressed MUC1 expression by
about 90%. F. MUC1-positive breast cancer cells, T47Ds, are treated with either bivalent Anti-MUC1* or the monvalent Fab, then analyzed by Western
for the presence of phosphorylated ERK1/2. Blots show the induction of ERK2 phosphorylation by bivalent Anti-MUC1* and inhibition of basal ERK1/2
phosphorylation after two days (2 d) treatment with the monovalent Fab.
doi:10.1371/journal.pone.0002054.g003
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PLoS ONE | www.plosone.org 6 April 2008 | Volume 3 | Issue 4 | e2054Figure 4. NM23 is a MUC1* ligand that stimulates cell growth. A. Lysate-supernatant mixtures from a panel of MUC1-positive breast cancer
cells were tested for the presence of a ligand capable of dimerizing a MUC1*1110-ecd peptide (membrane proximal 45 amino acids of the extracellular
domain: 1110–1155). Lysate-supernatant mixtures were incubated with nanoparticles bearing either a control peptide or a MUC1*1110-ecd peptide,
histidine-tagged at the C-terminus. A nanoparticle solution color change from pink to a purple/blue indicates that a species in the mixture has
simultaneously bound to 2 or more MUC1*1110-ecd peptides. B. Bivalent (bv) Anti-MUC1* (0.77 ug) is added to nanoparticles bearing either a control
peptide (Row A) or MUC1*1110-ecd, peptides (Row B). Antibody binding to two peptides on separate nanoparticles causes nanoparticle aggregation
and the solution color change from pink to purple/blue. In Row A, wells 3–5, this aggregation is inhibited by the addition monovalent Anti-MUC1*
Fab (mv Fab). C. NM23 at 0.05, 0.1 or 0.2 uM, (Rows A, B and C respectively) is added to nanoparticles bearing MUC1*1110-ecd peptides (Columns 2–5).
Added NM23 induces a color change, presumably as NM23 dimers bind to nanoparticle-immobilized MUC1*1110-ecd peptides. The addition of
monovalent Anti-MUC1* (mv Fab), in Columns 3–5, inhibits the color change. D. Conditioned media from MUC1-positive breast cancer cells, T47Ds,
and MUC1-negative rat fibroblasts, 3Y1s, was mixed with beads bearing the MUC1*1110-ecd peptide. Immunoprecipitated species were then analyzed
by western, wherein the gel was blotted with an anti-NM23 antibody. The western blot shows that T47Ds secrete NM23 while 3Y1s do not. E. Surface
plasmon resonance (SPR) was used to detect direct binding between NM23 (15 nM) and MUC1*1110-ecd peptides. The sensogram shows that 1044
RUs of NM23, injected at 15 nM, bound to a surface bearing MUC1*1110-ecd peptides (solid line) but no NM23 bound to a control surface bearing an
irrelevant peptide (dashed line). F. Stimulation of T47D breast cancer cell growth by NM23 is dependent upon MUC1 expression. Exogenous NM23
added to T47D breast cancer cells stimulates growth and produces bell-shaped curve indicative of receptor dimerization. Growth is greatly reduced in
cells stably expressing MUC1-specific siRNA, compared to cells expressing a control siRNA. Western blot quantifies the siRNA suppression of MUC1.
doi:10.1371/journal.pone.0002054.g004
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ligand of MUC1, we would expect to see more growth stimulation
in the cells transfected with the control siRNA than in the cells
transfected with siRNA that suppressed MUC1. Exogenous NM23
was added at concentrations in the same range as those shown to
bind to MUC1*1110-ecd peptides in the SPR experiments. The
addition of exogenous NM23 stimulated the growth of the cancer
cells in which MUC1 was not suppressed. A bell-shaped growth
curve indicative of receptor dimerization was generated. The
siRNA suppressed cells were weakly stimulated. Western blot
analysis shows that the siRNA suppressed MUC1 expression by
about 75% (Fig. 4F). These results are consistent with the idea that
NM23 act as a growth factor for the MUC1* receptor.
MUC1 protein contains a self-aggregation domain
Our finding that the major species in cultured cancer cells and
on cancerous tissues is MUC1*, the cleaved form, led us to wonder
if MUC1 cleavage had any functional significance. We designed a
nanoparticle experiment to investigate whether or not a portion of
MUC1 that is shed from the cell surface after cleavage could bind
to the MUC1*1110-ecd peptide as previously suggested [20].
Peptides corresponding to products of proposed cleavage sites
were synthesized with histidine-tags and immobilized on gold
nanoparticles. Various combinations of possible binding pairs were
mixed together to test for interaction. None of the peptides that we
tested bound to the MUC1*1110-ecd peptide. However, unexpect-
edly, we discovered that a portion of the MUC1 protein self-
aggregates. A non-repeating 25 amino acid sequence (N-1084-
1109-C) that is immediately amino terminal to the MUC1*1110-ecd
portion, which we call MUC1SAD (self-aggregation domain), self-
aggregates (Fig. 5A). In a follow up experiment, we found that a
shifted frame peptide (N-1101-1148-C) consisting of most of the
sequence of MUC1*1110-ecd but extending nine (9) additional
amino acids into the MUC1SAD region also self-aggregates, but to
a lesser degree than the full MUC1SAD (Fig. 5B). Of note, this self-
aggregating domain of MUC1 lies within a larger conserved motif
called an SEA domain [31].
Discussion
Our study examined the expression patterns of, and the growth-
promoting activities of, full-length MUC1 and its cleavage
product, MUC1*. For many years researchers had observed a
link between the aberrant expression of MUC1 and cancer. It had
also been known for many years that MUC1 undergoes cleavage
to generate a low molecular weight fragment, which remains
membrane-bound, plus a soluble high molecular weight portion
that can be shed from the cell surface. However, studies needed to
be done that examined the roles of each fragment individually. To
this end, we produced and characterized a novel antibody to the
MUC1 protein that is able to distinguish the 20–35 kDa
membrane-bound fragment from the remaining 200
+ kDa amino
terminal portion. We call this antibody anti-MUC1*. The use of
this novel antibody along with another antibody, VU4H5, that
recognizes the high molecular weight soluble fragment, revealed
that MUC1* is the predominant species on cultured cancer cells
and on tumor tissue and is surface-expressed. Full-length MUC1 is
the minor species and its expression appears to be restricted to the
cytoplasm. We therefore generated a MUC1* construct,
Figure 5. MUC1 has a self-aggregation domain (SAD) immediately N-terminal to MUC1*. A. Degenerate peptides derived from the
membrane-proximal extracellular domain of MUC1, as well as a portion of the tandem repeats, were separately attached to pools of nanoparticles.
Aliquots of nanoparticles, each bearing a different peptide sequence, were mixed together to test for possible interaction between one peptide and
another, or for self-interactions. Interactions among nanoparticle-immobilized peptides are seen as a color change from pink to purple/blue. The well
in the upper left corner shows that the peptide MUC1SAD self-aggregates. No other peptides tested bound to each other. B. Wells 1–3 contain
nanoparticles bearing histidine-tagged peptides of a single sequence. Well 1, containing MUC1*1110-ecd (N-1110-1154-C) does not self-aggregate as
evidenced by the pink solution color. MUC1*SAD, (N-1084-1109-C), which is immediately adjacent to MUC1*1110-ecd, clearly self-aggregates as the
solution color turned a deep purple/blue (Well 3). A third peptide MUC1ecd-EXT (N-1101-1148-C) comprised of 39 amino acids of MUC1*1110-ecd and
extending nine additional amino acids into the self-aggregation domain (SAD), albeit to a lesser degree (Well 3).
doi:10.1371/journal.pone.0002054.g005
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extracellular domain) to mimic the species found on tumor tissue.
The expression of this minimal MUC1* fragment into MUC1-
negative cells is sufficient to stimulate cell proliferation and to
render cells resistant to death induced by chemotherapy agents.
We further demonstrated that treating cells that express MUC1*
with bivalent anti-MUC1* stimulates cellular proliferation and
transient phosphorylation of ERK1/2. These results suggest that
MUC1* might act as a receptor for an extracellular factor that
promotes MUC1* dimerization, activation of the MAP kinase
pathway and thus tumor cell proliferation.
Ligand fishing experiments that we performed identified NM23
as a potential ligand for MUC1*. NM23 is normally cytoplasmic
but is often secreted by tumor cells [26]. Our in vitro experiments
showed that NM23 binds to MUC1* extracellular domain
peptides with nanomolar affinity. Further, the addition of
exogenous NM23 to MUC1*-expressing tumor cells stimulated
growth, while siRNA suppression of MUC1 in those same cells,
suppressed that stimulation. Importantly, direct binding between
NM23 and MUC1* peptides was detected for the same
concentration range at which NM23 stimulated cancer cell
growth. NM23 has been simultaneously linked to both metastasis
suppression [32] and metastasis promotion [33]. It should also be
noted that stimulation of tumor cells with NM23 produces the bell-
shaped growth curve that is characteristic of ligand-induced
receptor dimerization. Notably, NM23 can be a monomer, dimer,
tetramer or hexamer depending on concentration [34] and thus its
function may depend on its multimerization state. For example, an
NM23 mutant, S120G, which inhibits hexamer formation but
preferentially form dimers is common in neuroblastomas [35]. It is
possible that mutations or expression levels of NM23 that result in
dimers as the major species could drive cell growth by stimulating
the MUC1* receptor for prolonged periods of time.
Previous studies reported that MUC1 is a co-receptor for
ErbB2, EGFR and FGFR3 [11,12]. However, our results argue
that MUC1* is capable of functioning as an independent growth
factor receptor. 3Y1 cells do not express ErbB2 and express very
minimal levels of EGFR and FGFR3. Yet, transfection of
MUC1*1110 into 3Y1 cells conferred growth factor receptor-like
activity. The introduction of MUC1*1110 stimulated growth,
increased survival and drove more cells into the G2/M phase
than did the transfection of the empty vector or full-length MUC1.
Our finding that MUC1 has a self-aggregation domain (SAD)
will require further study. The self-aggregation domain of MUC1
may promote the clustering of full-length MUC1 and serve to
occlude the ligand binding site of MUC1*. Cleavage at a site that
releases the self-aggregation domain could render the membrane-
attached MUC1* accessible to activating ligands. MUC1’s SAD
region is a part of a larger, conserved SEA domain [31] that is
found on several cell surface proteins and has been shown to
undergo self-cleavage. It is unclear as to whether or not self-
aggregation is inherently characteristic of SEA domains. Thus, it is
tempting to speculate that cleavage and release of a self-
aggregation domain may be a conserved mechanism that allows
cell surface proteins to change their function.
In summary, we have found that the predominant form of the
MUC1 protein on the surface of tumor cells and tissues is a low
molecular weight species that we call MUC1*. Treatment of cells
expressing MUC1* with a bivalent ligand stimulates tumor cell
growth. The construct MUC1*1110, truncated after only forty-five
(45) amino acids of the extracellular domain, may represent the
minimal region of MUC1 necessary for its oncogenic function.
Thus, a new class of potent anti-cancer therapeutics could be
designed around agents that interfere with the interaction between
the extracellular domain of MUC1*1110 and its activating ligands.
The more immediate implications of our findings are for cancer
diagnostics. The aberrant expression of MUC1 has been
correlated with recurrence and life expectancy for prostate cancer
[36,37]. These studies were based on measurements of the full-
length protein or full-length transcript but were blind to the
cleaved form, MUC1*. Our novel antibody, Anti-MUC1*,
specifically stains MUC1*, but does not stain the full-length
protein on tissues. A biopsy test that quantifies the amount of
MUC1* that is accessible to its activating ligands would be a more
accurate prognostic indicator than tests that detect portions of
MUC1 that are typically shed from the surface of tumor cells.
Methods
Cell Lines and Culture
Human embryonic kidney HEK 293 cells, rat 3Y1 fibroblasts
and human HCT116 colon carcinoma cells were cultured in
DMEM supplemented with 10% heat inactivated fetal bovine
serum (HI-FBS), 100 unit/ml penicillin, 100 mg/ml streptomycin,
2 mM L-glutamine and further supplemented with and 600 mg/
ml G418 sulfate (HyClone, Logan Utah) to culture transfectants.
Breast carcinoma cells T47D, ZR-75-1 (CRL-1500) and ZR-75-30
(CRL-1504) cells were cultured in RPMI 1640 medium containing
10% HI-FBS, 100 units/ml penicillin, 100 mg/ml streptomycin,
2 mM L-glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose,
10 mM HEPES, and 1.0 mM sodium pyruvate. Medium was
further supplemented with 0.5 mg/ml puromycin (CALBIO-
CHEM) for siRNA experiments.
Anti-MUC1* Antibodies
Polyclonal: Rabbits were immunized with a MUC1*1110-ecd
peptide conjugated at the C-terminus with KLH and affinity
purified by column chromatography. Papain digestion, then
purification over a protein A column produced monovalent Anti-
MUC1*, collected from the flowthrough (QCB). Mouse monoclonal
antibodies were generated via immunization with the same peptide.
Western Analysis
Cell pellets were lysed in cold RIPA buffer plus protease
inhibitors. Protein concentration was determined using a BCA
Assay Kit (Pierce). 40 mg of lysates were resolved on 6% or 12%
acrylamide SDS-PAGE gels. Proteins were transferred to Im-
mobilon P membrane (Millipore) under semi-dry conditions.
Membranes were blocked for 1 hour in 5% nonfat dry milk in
PBST (PBS containing 0.05% Tween-20) and hybridized
overnight in 5% nonfat dry milk in PBST with Anti-MUC1*
(1:500; Minerva Biotechnologies), VU4H5 (1:200, Santa Cruz),
Ab-5 (1:200, LabVision). Membranes were washed three times in
PBST, and secondary detection was done using 1:10,000 dilutions
of HRP-conjugated anti-mouse, anti-rabbit, or anti-Armenian
hamster antibody (Jackson ImmunoResearch Labs). Membranes
were washed three times, and chemiluminescent detection was
done using ImmuneStar reagent (Bio-Rad).
Deglycosylation
Whole cell lysates from indicated cell lines were incubated for
24 hours in the presence of PNGase, O-glycosidase, and
Neuraminidase (New England Biolabs), according to manufactur-
er’s directions.
Immunohistochemistry of Tissues
Serial sections from formalin fixed, paraffin embedded human
tissue specimens were probed with Anti-MUC1* at 0.5 mg/ml or
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were processed using an automated stainer (Dako and LabVision)
with Dako products and included antigen retrieval with a low (6.0)
pH citrate buffer (Dako). Tissues were obtained from untreated
patients.
Survival Assays
Survival of 3Y1 transfected with either MUC1*1110 or
full-length MUC1 in the presence of chemotherapeutic
drugs. Nomenclature for single cell clones of transfectants is
‘‘parent cell name/MUC1 or MUC1*/clone #’’. 5 6 10
5 cells/
well were plated into 6 well plates in DMEM with 10% serum and
G418. The next day, AraC was added to 3Y1 transfectants to a
final concentration of 100 mM. Experiments were performed in
triplicate. DMSO was added to control wells. After 30 hours cells
were trypsinized and resuspended then treated with trypan blue.
Live cells were counted using a hemocytometer.
Immunoprecipitation
T47D cell lysate (500 mg) was pre-cleared with 25 ml of Protein
G Magnetic Beads (New England Biolabs) for 1 hour at 4uC with
rotation, and incubated with Ab-5 or Anti-MUC1* antibodies pre-
bound to 25 ml Protein G Magnetic Beads for 1 hour at 4uC with
rotation. Beads were magnetically immobilized, washed three
times with PBS, and eluted by boiling in SDS-PAGE loading
buffer for 10 minutes. Precipitated proteins were resolved by 6%
SDS-PAGE for Western analysis using VU4H5 antibody and 12%
SDS-PAGE for Western analysis using the Anti-MUC1* antibody.
Immunofluorescence of Cancer cells
3.4 6 10
4 cells per well were plated in 8-well chamber slides
(Nunc)inRPMIwith10%serum(T47D andCRL-1504)orDMEM
with 10% serum and G418 (3Y1 and HCT116 transfectants). Next
day, cells were washed once in PBS, fixed for 5 minutes with 4%
paraformaldehyde in Sodium Cacodylate buffer (0.1 M, pH 7.4).
Cells were blocked overnight in 0.25% donkey serum and 0.25%
BSA in PBS, and hybridized for one hour in Anti-MUC1* (1:250
dilution of 0.77 mg/ml solution) and VU4H5 antibody (Santa Cruz;
1:50 dilution) 0.25% donkey serum and 0.25% BSA in PBS. Cells
were washed 3-times for 10 minutes in PBS, and incubated in anti-
rabbit Alexa 555 (Invitrogen) and anti-mouse Alexa 488 (Invitrogen)
for 30 minutes. Cells were washed 3 times in PBS for 5 minutes.
Cover glass was mounted on top of slides with anti-fade mounting
medium (Biomeda) and sealed with nail polish.
Cell Cycle Analysis
HCT116 clones transfected with MUC1, MUC1*1110, or empty
vector were maintained in DMEM with G418 and 0.5% FBS for
48 hours. Medium was changed to DMEM with G418 and
indicated FBS amounts. After 18 hours, cells were washed once in
PBS, fixed in 90% Methanol, and stained in PI buffer containing
Propidium Iodide, RNase A (Invitrogen), 0.1% Triton X-100
(Sigma) in PBS. Analysis was performed on a FC500 Analyzer
(Beckman Coulter) WinCycle32 software (Phoenix Flow Systems),
and G2/G1 ratios were calculated.
MUC1* peptide precipitation and NM23-H1 Western blot
MUC1*1110-ecd-His6 peptide was added to a final concentration
of 2.5 nM in 200 ml of a 5% suspension of Ni-NTA-Magnetic
beads (Qiagen) and incubated at 4uC for 1 h. The bead-peptide
conjugates were magnetically immobilized and washed 3 times
with 500 ml of lysis buffer (50 mM NaH2PO4, 300 mM NaCl,
10 mM imidazole, pH 8.0). 1 mL of cell culture supernatant from
indicated cell lines was added to peptide-bead conjugates, and
incubated overnight at 4uC. Precipitate-bound beads were washed
3-times in wash buffer. Precipitated proteins were eluted by boiling
in buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole,
pH 8.0) for 10 minutes. Samples were mixed with SDS-PAGE
sample buffer and boiled for 10 min for resolution on a 4–20%
SDS-PAGE gradient gel. Gel was probed with anti-NM23-H1
(SC-343, Santa Cruz).
Generation of constructs and transfectants
3Y1 and HCT116 MUC1 and MUC1*1110 transfect-
ants. Full-length MUC1 cDNA was assembled by piecing
together DNA from different EST clones obtained from ATCC
(American Type Culture Collection, Manassas VA) and from
RTPCR carried out on total RNA from T47D cells. The final
coding sequence containing 41 repeats was cloned in between the
EcoRI and BamHI sites of the plasmid pIRES2-EGFP (Clontech).
The MUC1*1110 expression construct was made by cloning in
frame the sequence corresponding to the C-terminal 145 amino
acids of MUC1 beginning at GTINV… and ending at
…AAAASANL after the nucleotide sequence for the signal
peptide. The MUC1 sequence containing constructs and the
vector plasmid were transfected into 3Y1 and HCT116 cells and
stable transfectants were selected by using G418 at concentration
of 600 mg/ml. The pool of transfectants were used to obtain single
cell clones by sorting with flow cytometer using VU4H5 (Santa
Cruz) for full-length MUC1 stable clones, and MUC1* rabbit
polyclonal antibody for MUC1*1110 stable clones. Single cell
clones were later characterized by FACS and by Western blot.
T47D MUC1 siRNA transfectants. T47D cells were stably
transfected with recombinant pSilencer 3.1-H1 puro plasmid
(Ambion, Applied Biosystems USA) containing siRNA inserts
using Lipofectin (Invitrogen). The sequence of the MUC1-specific
siRNA hairpin was as follows: 59-GCAGCCTCTCGATAT-
AACC-ATCTCGAGG-GGTTATATCGAGAGGCTGC-39. The
hairpin sequence is in italics and the sense and the antisense 19
nucleotide siRNA sequence appears from 59 to 39. We used the
pSilencer puro Negative Control Pasmid supplied by the
manufacturer as our negative control for siRNA effect. This
plasmid encodes a hairpin siRNA whose sequence is not found in
the human, mouse or rat genome databases. Transfected cells
were selected with media containing 0.5 mg/ml puromycin. Knock
down of MUC1 protein was evaluated by Western analysis using
Anti-MUC1* antibody.
Cell growth assays
Clonogenic Assay. Single cell clones of 3Y1 cells transfected
with either full-length MUC1, MUC1*1110, or empty vector were
used. Cells were plated at 1000 cells per 100 mm dish in DMEM
media containing 10% fetal bovine serum, penicillin/streptomycin
and G418 (600 mg/ml). Cells were grown for 9 days and then fixed
in 4% paraformaldehyde for 15 minutes at room temperature.
Dishes were washed with water and then stained with 1% crystal
violet in 70% methanol for 20 minutes at room temperature.
Dishes were washed three times with water and allowed to dry
overnight at room temperature. To extract the dye, 10% acetic
acid was added to each dish and incubated for 20 minutes at room
temperature while shaking. Dye/acetic acid solution was diluted
1:4 in water and the absorbance was measured at 590 nm.
Antibody Stimulation Assays. ZR-75-30 cells, 6000/well,
were plated in 96 well plates and zero hour cell count taken the
next day when media was changed to 0.1% serum. Anti-MUC1*
was added every 24 or 48 hours (noted in figure) and cells were
grown until first plate reached 80% confluency. Control
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Cruz), monovalent Rabbit anti-mouse IgG Fab (Jackson
Immunoresearch) and anti-hemagglutinin (IgG2b: Santa Cruz)
were added every 24 hours at the same concentrations as anti-
MUC1* antibodies. Control HEK293 cells, 4000/well (faster
doubling time) were plated as above. Anti-MUC1* was added
every 24 hours until plates were 80% confluent. Monovalent Anti-
MUC1* was added to ZR-75-30 cells as described for bivalent
antibody with the exception that cells were counted after
144 hours, with antibody added every 24 hours. HEK293 cells
were treated with monovalent Anti-MUC1* according to the
protocol used by bivalent Anti-MUC1*. All experiments
performed in quintuplicate; cells counted on a hemocytometer.
MUC1 siRNA expressing and Control siRNA cells, stably
transfected, were plated 2000/well in 96-well plates. After
overnight attachment media was changed to 2% serum and zero
hour cell count was taken. Anti-MUC1* antibody was added every
48 hours and the final cell count was taken at 72 hours.
NM23 growth stimulation assay. T47D cells were stably
transfected with either MUC1-specific siRNA or a non-specific
siRNA, Control siRNA. Cells were plated 10,000/well, six wells/
condition in 96-well plates. After overnight attachment in full
serum-containing medium, medium was changed to 3% serum-
containing medium and zero hour cell count was taken. Bovine
NM23 (Sigma N-2635) was added to a final concentration of 0,
0.1, 0.3, 1, 3, 10, or 30 nM every 48 hours. Cells were counted
after five days of NM23 stimulation, and percent growth was
calculated relative to the growth of cells to which no NM23 was
added. Standard deviations of percent growth are plotted as error
bars.
ERK1/2 activation by MUC1* antibody stimulation
CRL-1500 cells were plated at 7.5610
5 cells per 60 mm tissue
culture dish in 3 ml RPMI. After overnight incubation the cells
were serum starved for 48 hours. Then medium was replaced with
2 ml of fresh serum free RPMI, and 2 mg of Anti-MUC1*
antibody was added to each plate, except for the negative control.
Stimulation was stopped at 5, 10, 20 and 40 minutes by aspirating
the media and adding RIPA buffer containing 1 mM Na3VO4 to
the plates. Cells were lysed for 10 minutes and detergent-insoluble
material was removed by centrifugation. Equal amounts of protein
were resolved on a 12% SDS-polyacrylamide gel and Western
analysis was performed using anti-phosoho-p44/42 (Cell Signaling
Technology).
Nanoparticle assays
MUC1* - ligand binding interaction. Histidine-tagged
MUC1*1110-ecd peptide or irrelevant peptide bearing nano-
particles were prepared by incubating 20 mL of 100 mM solution
of the peptide per 100 mL of the NTA-Ni
++ gold nanoparticle
solution. 30 mL of the peptide-bound nanoparticle solution was
added into each well of a 96 well plate, along with 40 mL of PBS
and 30 mL of lysate/supernatant mixture from MUC1-positive
tumor cell lines T47D, ZR-75-1, ZR-75-30 and CRL-1902. Color
change was recorded after 3 hours.
MUC1*- NM23 interaction. To nanoparticles presenting
MUC1*1110-ecd or the irrelevant GDV peptide, 70 mL PBS was
added followed by the indicated amount of human recombinant
NM23 protein. For inhibition with the monovalent Anti-MUC1*
Fab, indicated amounts (Fig. 4C) of the antibody were added
immediately before adding the NM23 protein. Color change was
recorded after 15 minutes.
Recombinant NM23 protein. The protein coding sequence
for human NM23 was amplified from NM23 cDNA clones
(OpenBiosystems) and cloned into pEXP2-DEST bacterial
expression vector using Gateway system (Invitrogen). NM23
plasmid was transformed into BL21 (DE3) pLysS cells and its
proteins were prepared using either standard IPTG induction or
MagicMedia E. coli protein expression media (Invitrogen). His-
tagged proteins were purified using NTA-Agarose (Qiagen)
methods using 250 mM imidazole for elution.
MUC1* - Anti-MUC1* interaction. Histidine-tagged
MUC1*1110-ecd peptides or irrelevant ‘‘GDV’’ peptides
(GGDVGDSGGDVGDSGGDVGDSH HHHHH) were
attached to NTA-Ni
++-SAM-coated nanoparticles. Peptide
bearing nanoparticles were prepared by incubating 10 mLo f
5 mM solution of the peptide per 100 mL of the NTA-Ni
++ gold
nanoparticle solution. 30 mL of the peptide-bound nanoparticle
solution was added into each well of a 96 well plate containing
70 mL PBS. Indicated amounts (Fig. 4D) of antibody were next
added. For competition experiments, the monovalent Anti-
MUC1* Fab was added immediately before adding MUC1*
antibody. Color change was recorded after 15 minutes.
Self-aggregation. 20 mL of each histidine-tagged peptide at
100 mM in PBS, were added to each well of a 96 well plate.
100 mL of gold nanoparticles presenting NTA-Ni
++ prepared
according to the method described in Bamdad [25,34], were
added to wells. Color change of the gold nanoparticles was
recorded after15 minutes.
Surface plasmon resonance
A Biacore3000 instrument and BiaEvaluation software was
used. Histidine-tagged MUC1*1110-ecd or irrelevant peptide
(HHHHHH-SSSSGSSSSGSSSSGGRGDSGRGDS) were immo-
bilized on separate flow channels of 5.7% NTA-Ni
++ SAM-coated
SPR chips, prepared in our lab as described in Bamdad [27].
35 mL plugs of NM23, purified bovine or recombinant human,
were injected into a constant flow stream of 5 uL/minute and
sensograms were recorded. NM23 purified from bovine liver
(Sigma N-2635) was diluted in PBS alone. Recombinant human
NM23 was produced in our lab and affinity purified over a NTA-
Ni
++ column. The protein was diluted in PBS with 15 mM
imidazole, which prevented binding to any exposed NTA-Ni
++
moieties on the chip surface. The chip surface in each flow
channel was used only once. Surfaces were not ‘‘regenerated’’ and
for each experiment, NM23 in solution was simultaneously
introduced to both the MUC1*1110-ecd peptide immobilized on
one flow channel and the control peptide immobilized on a second
flow channel. Affinities were measured over a wide range of
concentrations using a 1:1 Langmuir model. Actual affinities may
vary as first order kinetics cannot adequately describe this system.
Supporting Information
Figure S1 Cells transfected with full-length MUC1 are cleaved
and yield both MUC1 and MUC1*. Single cell clones of 3Y1 cells
transfected with either full-length MUC1, MUC1*1110 or empty
vector were analyzed by western blot. Upper gel was blotted with
VU4H5 and lower gel was blotted with anti-MUC1*. Nomencla-
ture for clones: ‘‘parent cell name/MUC1 or MUC1* or Vect/
clone #’’. Lanes 2 and 3 contain cleared lysates of MUC1*1110
clones and show no high molecular weight species. Lanes 4 and 5
are from clones of full-length transfectants and show both the high
molecular weight and well as low molecular weight proteins. Lanes
7 and 8 are MUC1-positive breast tumor cell lines for comparison.
Found at: doi:10.1371/journal.pone.0002054.s001 (1.86 MB TIF)
Figure S2 Anti-MUC1* bivalent antibodies stimulate growth of
MUC1-positive tumor cells control antibodies do not. The growth
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the addition of bivalent (bv) Anti-MUC1* and inhibited by the
addition of the monovalent form, Anti-MUC1* mv. A panel of
control antibodies was added: anti-His (IgG1), anti-HA (hemag-
glutinin IgG2b), Mouse IgG (total IgG) and Rabbit IgG mv, which
is the monovalent Fab of a rabbit anti-mouse antibody. The
addition of bivalent antibody produces the bell-shaped growth
curve that is characteristic of receptor dimerization while the
addition of monovalent Anti-MUC1* inhibited growth. The
control antibodies whether bivalent or monovalent had no effect.
Found at: doi:10.1371/journal.pone.0002054.s002 (1.29 MB
DOC)
Figure S3 MUC1* ligand fishing and N-terminal sequencing
identifies NM23 as MUC1* ligand. MUC1*1110-ecd or an
irrelevant peptide (ARKCSLTGKWTNDLGSNMTHHHHHH)
were immobilized on NTA-agarose beads. Cell lysate prepared
from roughly 24 6 106 T47D cells prepared in PBS containing
(0.1% NP40) was allowed to bind to the each type of peptide
immobilized beads, washed extensively and eluted with 250 mM
imidazole containing PBS. Aliquots of eluates from the two types
of beads, either directly or from TCA precipitates of the eluates,
were separated on a 12% SDS-PAGE gel. The protein bands were
visualized with silver staining and N-terminal sequence was
determined for the protein bands that were specific for the
MUC1*1110-ecd immobilized beads.
Found at: doi:10.1371/journal.pone.0002054.s003 (8.19 MB TIF)
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